Boswellia serrata gum extract (Aflapin), sodium hyaluronate (HyaMax), undenatured type II collagen (UC-II).
Each cap contains undenatured type II collagen (UC-II) 40 mg, Boswellia serrata gum extract (Aflapin) 100 mg, and sodium hyaluronate (HyaMax) 50 mg.
Vylex contains UC-II, a novel undenatured type II collagen & Aflapin, a novel Boswellia serrata gum extract standardized to 20% AKBA, and a novel sodium hyaluronate obtained from fermentation for higher stability (HyaMax).
UC-II & Aflapin are patented active ingredients & support joint health by their disease-modifying anti-inflammatory & cartilage protecting pathways. Research in multiple clinical trials have shown safety & efficacy in reducing joint pain (from 5-7 days), stiffness & increasing physical function & mobility, and cartilage thickening via ultrasound & MRI imaging.
These disease-modifying mechanism of action have been evaluated through multiple pre-clinical studies.
Activates T regulatory (Treg) cells, which increase the production of anti-inflammatory mediators such as IL-4, IL-10 & TGF-β, which in turn, stimulate chondrocytes to synthesize cartilage matrix components.
Inhibits production of cartilage degrading enzymes, matrix metalloproteinases MMP-3 & MMP-13, which prevents cartilage breakdown.
Inhibits activities of killer T cells & T-helper cells (Th cells) in the joint, which prevents catabolism of cartilage.
Reduce the production of pro-inflammatory mediators such as 5-lipoxygenase (5-LOX), IL-1β, TNF-α, IL-2 & IL-17.
Adjunctive therapy for osteoarthritis.
1 capsule daily for 3-6 months.
There is no experience with clinically significant overdosage. Toxicological studies indicate that there are no significant acute & sub-chronic toxic effects (oral LD50 of more than 5,000 mg/kg in animals) & it has a broad spectrum safety profile. However, in case of accidental overdosage, symptomatic treatment should be employed under guidance of a physician.
Hypersensitivity to the active substances or to any of the excipients such as collagen, Boswellia serrata & sodium hyaluronate.
No known special precautions.
Insufficient information currently, not recommended for pregnancy & lactation.
Safety & tolerability have been shown in multiple clinical trials on patients with OA. There were no significant changes in hematologic, biochemical, vital signs & urinary parameters. Minor adverse events reported were headache & GI-related, which were similar to the placebo group & not due to the medicine.
No known interaction with other drugs.
Store below 30°C away from sunlight & moisture.
M01AX - Other antiinflammatory and antirheumatic agents, non-steroids ; Used in the treatment of inflammation and rheumatism.
Sign Out
Continue with Google
Sign Up With Email
Already a member?
Sign In
